Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingObservational

Proteomics and Radiomics Research of Breast Cancer Markers in Tissue, Interstitial Fluid and Serum

NCT ID: NCT01042548Sponsor: University of PittsburghLast updated: 2026-05-07

Summary

The current study is a case control study involving comparisons of tissue interstitial fluid from breast cancer and adjacent non-cancerous tissue as well as that from benign breast lesion and its adjacent non-diseased tissue for a distinguishable breast cancer profile. The purpose of this research is to collect fresh breast nodule/cancer and surrounding non-cancerous tissue for proteomic studies of the interstitial fluid to identify a profile distinguishing breast cancer which will also permit future research on stored interstitial fluid, blood or tissue samples. Specific markers identified from interstitial fluid study will be investigated in blood samples to develop serum markers for breast cancer diagnosis and prognosis. Additionally, we will perform both prospective and retrospective research on breast cancer involving clinical, demographic, epidemiologic information, treatment, follow-up and outcomes on breast nodule/cancer cases collected.

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * All subjects ≥ 18 years of age undergoing surgery for indeterminate breast nodules, breast tissue reduction, prophylactic mastectomy, and all subjects with newly diagnosed invasive breast cancer will be eligible to participate. If invasive breast cancer or suspicion of invasive breast cancer, target lesion must measure ≥ 1.0 cm on breast imaging before core biopsy. Exclusion Criteria: * Anyone \< 18 years of age. * Multiple synchronous primary malignancies from different organ systems.

Study locations (1)

UPMC St. Margaret

Pittsburgh, Pennsylvania, 15215

Recruiting
Laura Chiesa · Contact
Min Sun, MD, PhD · Contact
Min Sun, MD, PhD · Principal Investigator
Proteomics and Radiomics Research of Breast Cancer Markers in Tissue, Interstitial Fluid and Serum | Cancerify